Taysha Gene Therapies financials
$4.990.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $5.5M | $0.00 | $2.0M | $2.3M | $2.0M | $1.8M | $1.1M | $3.4M | $3.6M | $4.7M |
| Gross profit | $0.00 | $0.00 | $5.5M | $0.00 | $2.0M | $2.3M | $2.0M | $1.8M | $1.1M | $3.4M | $3.6M | $4.7M |
| Gross margin | — | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$47.3M | -$43.5M | -$28.3M | -$34.0M | -$26.8M | -$21.4M | -$19.9M | -$25.9M | -$21.3M | -$24.3M | -$16.2M | -$16.3M |
| Net income | -$46.6M | -$42.4M | -$27.9M | -$32.7M | -$26.9M | -$21.5M | -$18.8M | -$25.5M | -$20.9M | -$24.1M | $47.7M | -$117.1M |
| Net margin | — | — | −507.8% | — | −1353.6% | −935.2% | −929.0% | −1427.5% | −1882.0% | −705.4% | 1324.7% | −2467.1% |
| Diluted EPS | $-0.13 | $-0.12 | $-0.08 | $-0.09 | $-0.09 | $-0.08 | $-0.07 | $-0.10 | $-0.09 | $-0.10 | $0.23 | $-0.93 |
| EBITDA | -$50.5M | -$43.2M | -$28.0M | -$33.7M | -$26.5M | -$21.1M | -$19.6M | -$20.8M | -$21.0M | -$24.0M | -$15.4M | -$15.3M |
| Operating cash flow | -$40.4M | -$40.9M | -$26.7M | -$24.2M | -$20.2M | -$22.0M | -$18.3M | -$21.6M | -$21.5M | -$19.8M | -$12.6M | -$21.4M |
| Free cash flow | -$40.4M | -$40.9M | -$27.0M | -$24.3M | -$20.2M | -$22.4M | -$18.3M | -$21.6M | -$21.8M | -$19.8M | -$16.1M | -$21.4M |
| Diluted shares | 369.0M | 366.6M | 358.2M | 353.3M | 298.0M | 269.3M | 268.6M | 267.8M | 232.8M | 231.2M | 211.3M | 125.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $455.4M | $276.6M | $319.8M | $297.3M | $312.8M | $116.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $49.3M | $49.0M | $50.1M | $50.9M | $41.1M | $42.5M |
| Total assets | $470.4M | $300.4M | $343.3M | $316.6M | $333.3M | $138.4M |
| Total liabilities | $83.2M | $88.4M | $96.4M | $97.6M | $84.6M | $83.3M |
| Shareholders' equity | $387.3M | $211.9M | $246.9M | $219.0M | $248.7M | $55.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology